Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models (original) (raw)

Abstract

Background

Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM).

Methods

14C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing human, rat, or mouse SGLT2 or SGLT1; 3H-2-deoxy-d-glucose uptake in L6 myoblasts; and 2-electrode voltage clamp recording of oocytes expressing human SGLT3 were analyzed. Graded glucose infusions were performed to determine rate of urinary glucose excretion (UGE) at different blood glucose (BG) concentrations and the renal threshold for glucose excretion (RTG) in vehicle or canagliflozin-treated Zucker diabetic fatty (ZDF) rats. This study aimed to characterize the pharmacodynamic effects of canagliflozin in vitro and in preclinical models of T2DM and obesity.

Results

Treatment with canagliflozin 1 mg/kg lowered RTG from 415±12 mg/dl to 94±10 mg/dl in ZDF rats while maintaining a threshold relationship between BG and UGE with virtually no UGE observed when BG was below RTG. Canagliflozin dose-dependently decreased BG concentrations in db/db mice treated acutely. In ZDF rats treated for 4 weeks, canagliflozin decreased glycated hemoglobin (HbA1c) and improved measures of insulin secretion. In obese animal models, canagliflozin increased UGE and decreased BG, body weight gain, epididymal fat, liver weight, and the respiratory exchange ratio.

Conclusions

Canagliflozin lowered RTG and increased UGE, improved glycemic control and beta-cell function in rodent models of T2DM, and reduced body weight gain in rodent models of obesity.

Introduction

Due in part to the increasing prevalence of obesity and the aging of the global population, type 2 diabetes (T2DM) is becoming an increasingly prevalent disorder [1]. While lifestyle interventions are effective means to improve glycemic control, as beta-cell loss ensues and illness progresses, patients require increasingly complex therapies involving combinations of antihyperglycemic agents, including insulin, in order to attain optimal glycemic control. Currently approved antihyperglycemic agents act by increasing insulin secretion, enhancing insulin sensitivity, or reducing glucose absorption. Despite the availability of a pharmacologic armamentarium containing a number of efficacious antihyperglycemic agents, fewer than 50% of patients achieve glycemic treatment goals set forth by expert societies [2].

In a normoglycemic person, approximately 180 grams of blood glucose (BG) is filtered by the glomerulus and is resorbed in the proximal tubule such that urinary glucose excretion (UGE) is negligible [3], [4]. As plasma glucose concentrations increase above normal, UGE remains negligible until the filtered glucose load begins to saturate the capacity of the renal glucose transporters. The plasma glucose concentration at which this occurs is called the renal threshold for glucose excretion (RTG). The majority of renal glucose resorption is mediated by sodium glucose co-transporter 2 (SGLT2), a high-capacity, low-affinity glucose transporter localized in the luminal membrane of early proximal renal tubular cells [3], [4]. Once transported by SGLT2 into the tubular cell, glucose is transported down its concentration gradient and into the renal interstitium by the facilitative glucose transporter 2 (GLUT2) [3], [4]. The filtered glucose not resorbed by SGLT2 is subsequently resorbed in more distal portions of the proximal tubule by SGLT1, a high-affinity, low-capacity glucose transporter and is transported from the proximal tubular cell into the renal interstitium by the facilitative GLUT1 [3], [4]. Although SGLT2 and SGLT1 are believed to transport the vast majority of glucose from the tubular lumen, other less well-characterized glucose transporters may also be involved in renal glucose resorption [5].

SGLT2 is expressed almost exclusively in the proximal tubule of the kidney [3], [4]. Mutations in the SLC5A2 gene encoding SGLT2 are found in persons with familial renal glucosuria (FRG) [6]; FRG is considered a benign condition, with affected individuals exhibiting glucosuria in the absence of hyperglycemia without alteration in other proximal tubular functions [6]. Recently, an SGLT2-null mouse was generated, its phenotype similar to that of persons with FRG [7]. SGLT1 is expressed predominantly in the intestine and to a lesser extent in the proximal tubule of the kidney [3], [4], [7]. Mutations in the SLC5A1 gene encoding SGLT1 are found in persons with glucose-galactose malabsorption [3], [7]. Persons with this disorder have severe, life-threatening diarrhea due to hexose malabsorption [3], [7]. Attesting to the minor role for SGLT1 in renal glucose resorption under normoglycemic conditions, these persons exhibit only minimal glucosuria [8]. If treated with a glucose-galactose-deficient diet, the growth and development of these individuals can be normal [3].

Phlorizin, a nonselective inhibitor of SGLT1 and SGLT2, reduces BG in preclinical models of T2DM [9] and, due to its insulin-independent mechanism of action, also lowers BG in models of type 1 diabetes [9], [10]. Due to its nonselective nature and its poor pharmaceutical properties, phlorizin is unsuitable for clinical development [11]. Recently, a number of selective, metabolically stable SGLT2 inhibitors have been discovered and are in clinical development to treat T2DM [12]–[14].

Canagliflozin, one of these SGLT2 inhibitors, is currently in clinical development. In this report, we describe the selectivity and potency of canagliflozin and characterize its effects on UGE, RTG, glycemic control, glucose-stimulated insulin secretion, energy expenditure, and body weight in preclinical models of T2DM and insulin resistance.

Materials and Methods

Ethics Statement

All animal work was conducted according to relevant national and international guidelines. Full details of the study was approved by Johnson & Johnson PRD IASCUC committee (SH-MET-3011).

Reagents and Chemicals

Canagliflozin was synthesized by Mitsubishi Tanabe Pharma Corporation, Medicinal Chemistry Laboratory (Toda, Saitama, Japan) [15]. Primers, vectors, and tissue culture media were purchased from Invitrogen (Carlsbad, California, USA). All other chemicals, unless otherwise specified, were purchased from Sigma (St. Louis, Missouri, USA).

Cell-based Assays

Sodium-dependent Glucose Uptake in Chinese Hamster Ovary (CHO) Cells Expressing SGLT1 and SGLT2 Co-transporters Parental CHO-K (CHOK) cells (commonly used mammalian cells for gene overexpression studies) expressing human or mouse SGLT1 and SGLT2 were utilized in this study. Cells were seeded into 96-well plates. Cells were then washed one time with 0.15 ml assay buffer (137 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 50 mM HEPES, pH 7.4) at 37°C. After the assay buffer was removed, 50 µl of fresh assay buffer with 5 µl of canagliflozin (0.3–300 nM) was added, followed by 10 minutes of incubation. Then, 5 µl of 6 mM alpha-methyl-d-glucopyranoside (AMG, a selective SGLT1/2 substrate)/14C-AMG (0.07 µCi) was added to the cells and incubated at 37°C for 2 hours. Next, the cells were washed 3 times with 0.15 ml ice-cold phosphate-buffered saline (PBS). After the final wash was aspirated, 50 µl of microscint 20 (Packard, Meriden, Connecticut, USA) was added. The plate was counted by TopCount (Packard, Meriden, Connecticut, USA).

The 2-deoxy-glucose (2-DG) Uptake in L6 Myoblast Cells

Cells from the rat skeletal muscle cell line, L6, was used to test the effect of canagliflozin on glucose transporter 1 (GLUT1) activity. Cells were maintained in Dulbecco's modified Eagle's medium containing 5.6 mM glucose supplemented with 10% fetal bovine serum, were seeded in 24-well plates at a density of 3.0×105 cells/well and cultured for 24 hours in an atmosphere of 5% CO2 at 37°C. Cells were rinsed twice with Kreb's ringer phosphate HEPES buffer (pH 7.4, 150 mM NaCl, 5 mM KCl, 1.25 mM MgSO4, 1.25 mM CaCl2, 2.9 mM Na2HPO4, 10 mM HEPES) and were pre-incubated with the solutions of canagliflozin (250 µl, 10 uM) for 5 minutes at room temperature. The transport reaction was initiated by adding 50 µl of 4.5 mM 2-DG (a substrate for GLUTs)/3H-2-DG (0.625 µCi) followed by incubation for 15 minutes at room temperature. The 2-DG uptake was halted by aspiration of the incubation mixture. Cells were immediately washed 3 times with ice-cold PBS. Samples were extracted with 0.3 N NaOH, and radioactivity was determined by liquid scintillation (Packard, Boston, Massachusetts, USA).

Two-electrode Voltage Clamp Recording of Oocytes Expressing Human SGLT3

The functional effects of canagliflozin on human SGLT3 were studied by 2-electrode voltage clamp electrophysiology using OpusXpress 6000A (MDS Analytical Technologies, Ontario, Canada) [16]. Oocytes were obtained from Nasco (Fort Atkinson, Wisconsin, USA). Stage V–VI oocytes were injected with 50 nl of either human SGLT3 mRNA (at 1 ng/nl) or distilled water (control) and incubated at 18°C in a calcium-free solution (92 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, 0.05 mg/ml gentamicin at pH 7.5) for 4–6 days before recording. The extracellular recording solution contained 92 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES at pH 7.5. Injected oocytes were impaled with 2 microelectrodes filled with 3 M KCl (resistance of ∼0.5–3 MΩ) and voltage clamped to −120 mV, at which continuous recordings were made (filtered at 5 kHz and sampled at 625 Hz). To establish the baseline in the absence of agonist, oocytes were first perfused for 85 seconds with a control buffer (92 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES at pH 7.5). Next, 50 µM 1-deoxynojirimycin (DNJ) was applied for 160 seconds, followed by co-application of imino sugars 1-deoxynojirimycin (DNJ, 50 µM) with either canagliflozin (10 µM) or dimethyl sulfoxide (DMSO) (0.1%) for 160 seconds. Finally, phlorizin (3 mM) was applied in the presence of 50 µM DNJ for 160 seconds. All experiments were performed at 22°C. Currents in the presence of 50 µM DNJ were subtracted from leak currents (currents in control buffer alone) to obtain DNJ-induced currents (IDNJ). Effects of compounds were calculated as: % Inhibition = 100×(IDNJ−Icmpd)/IDNJ, where Icmpd is the DNJ-induced and leak-subtracted current in the presence of a compound or DMSO. Due to lack of effect at the highest dose tested, a dose-response relationship was not examined.

In Vivo Studies with Animal Models

Animals and Canagliflozin Administration

Four rodent models were used in these experiments: (1) male C57BL/6J mice fed with a high-fat diet (D-12492 with 60 kcal% fat, Research Diets, Inc, New Jersey, USA) (diet-induced obese, insulin resistantmice [DIO]); (2) male C57BL/ksj-db/db hyperglycemic mice; (3) male Zucker fatty (ZF) obese, insulin resistant rats; and (4) male ZDF obese, hyperglycemic rats. All animals were housed according to standard procedures following a protocol approved by the IACUC in Drug Discovery at Johnson & Johnson Pharmaceutical Research & Development, LLC. Canagliflozin was formulated in 0.5% hydroxypropyl methylcellulose and administrated via oral gavage at 10 ml/kg.

Renal Glucose Handling

Two separate graded glucose infusion (GGI) studies were performed to characterize renal glucose handling in both untreated and treated ZDF rats. In both experiments, rats were anesthetized with thiobutabarbital (100 mg/kg); a catheter was inserted into the jugular vein for glucose infusion; another catheter was introduced into the bladder to collect urine; and a graded GGI was performed (infusion rate increased from 1.5 ml/kg/h to 6.0 ml/kg/h of 10% glucose over 90 min) to increase BG levels. In the first study, the GGI increased BG from overnight-fasted values of approximately 200 mg/dl to approximately 475 mg/dl. In the second experiment, insulin was infused (3 U/ml, 0.7 ml/kg/h) for 60 minutes to lower BG levels to approximately 25 mg/dl, and then the GGI was performed to increase BG to approximately 300 mg/dl over 90 minutes. Blood and urine samples were collected for each 5-min interval to measure glucose and creatinine levels. The RTG was determined as described below.

Determining RTG

The relationship between UGE and BG is commonly described as a threshold relationship in which there is little UGE when BGRTG, where the filtered glucose load is equal to the BG concentration multiplied by the glomerular filtration rate (GFR). The idealized threshold relationship in which UGE is 0 whenever BG is below RTG, and then increases with the filtered glucose load when BG>RTG, can be written mathematically as [17], [18]:

	(1)

Values of RTG were determined using nonlinear regression (nlinfit in Matlab version 7.10) with Equation 1 and the measured BG and UGE values.

Reduction of Hyperglycemia in Diabetic Rodent Models

To examine the effect of canagliflozin on hyperglycemia, single doses of canagliflozin (0.1, 1, and 10 mg/kg) were administered to overnight-fasted db/db mice. BG levels were monitored at 0, 0.5, 1, 3, 6, and 24 hours after dosing. Canagliflozin was also administered to ZDF rats at varying doses (3–30 mg/kg) for 4 weeks to evaluate its effect on BG control and pancreatic beta-cell function. BG levels were monitored weekly, and HbA1c, plasma glucose, and insulin levels were determined at the end of the 4-week treatment. An oral glucose tolerance test (OGTT) (2 mg/kg of body weight, given by gavage) was conducted in ZDF rats after 4 weeks of treatment. Blood was sampled at 0, 30, 60, and 120 minutes after glucose challenge from the tail vein for measurement of BG levels using a glucometer (One Touch Ultra, LifeScan, Milpitas, California, USA) and plasma insulin using ELISA method (ALPCO, Salem, New Hampshire, USA).

Body Weight Control Studies in Obese Mice and Rats

The effects of canagliflozin on body weight gain were evaluated in DIO mice and ZF rats. DIO mice received a 4-week treatment of canagliflozin at 30 mg/kg. Body weight, food intake, and BG levels were monitored weekly. UGE and indirect calorimetry were conducted in the fourth week of treatment during the compound treatment. In another study, ZF rats were treated with canagliflozin at 3 mg/kg for 3 weeks. Body weight, food intake, and BG were measured weekly during the 19-day treatment period. UGE, body fat, and indirect calorimetric studies were conducted at the end of this study.

Data Analysis

Statistical analysis was performed using the program Prism (Graphpad, Monrovia, California, USA). Differences between groups were evaluated using 1-way analysis of covariance with Dunnett's multiple comparison test or student's _t_-test (unpaired), as appropriate. Probabilities less than 5% (P<0.05) were considered to be statistically significant. Fifty-percent inhibitory concentration (IC50) and 95% confidence interval (CI) were determined by nonlinear least-squares analysis using a 4-parameter logistic model. All data are presented as mean ± standard error.

Results

Effect of Canagliflozin on AMG Uptake in CHO Cells Expressing SGLTs and 2-DG Uptake in L6 Myoblast Cells

In a concentration-dependent fashion, canagliflozin inhibited Na+-dependent 14C-AMG uptake in CHO-hSGLT2 cells, with an IC50 of 4.4±1.2 nM. Similar IC50 values were obtained in CHO-rSGLT2 and CHO-mSGLT2 cells (IC50 = 3.7 and 2.0 nM for rat and mouse SGLT2, respectively). Canagliflozin inhibited 14C-AMG uptake in CHO-hSGLT1 and mSGLT1 cells with IC50 of 684±159 nM and >1,000 nM, respectively. The IC50 values for hSGLT1 and hSGLT2 are similar to previously reported values for canagliflozin [19]. Figure 1 represents results from a typical experiment. At 10 µM, canagliflozin inhibited the facilitative (non-Na+-linked) GLUT-mediated 3H-2-DG uptake in L6 myoblasts by less than 50% (Table 1).

Figure 1. Inhibitory effects of canagliflozin on human SGLT1 and human SGLT2.

The inhibitory effect of canagliflozin on 14C-AMG uptake in CHOK-hSGLT1 and CHOK-hSGLT2 has been measured in 5 experiments. A typical inhibitory effect on CHOK-hSGLT1 (Panel A) and CHOK-hSGLT2 (Panel B) from a single experiment is presented here.

Table 1. Effects of canagliflozin on SGLT1-, SGLT2-, and facilitative glucose transporter-mediated glucose transport, and on SGLT3-induced currents.

Effects of Canagliflozin on hSGLT3 Exogenously Expressed in Oocytes

It has been reported recently that SGLT3 functions as a glucose sensor [20]. To explore the effects of canagliflozin on the function of this protein, human SGLT3 was expressed in oocytes. In sham (water)-injected oocytes, imino sugars 1-deoxynojirimycin (DNJ, 50 µM) did not induce currents. By contrast, ooctyes injected with human SGLT3 mRNA expressed significant DNJ-sensitive currents (−1.6±1.1 nA [n = 14] for sham-injected versus 43.4±2.9 nA [n = 60] for SGLT3-injected oocytes; P<0.05). In sham-injected oocytes, canagliflozin (10 µM) or phlorizin (3 mM) alone in the presence of 50 µM DNJ did not affect currents. In SGLT3-injected oocytes, DMSO and canagliflozin 10 µM inhibited DNJ-induced currents by 15.6±3.1% (n = 5) and 23.4±4.3% (n = 9), respectively. The difference between DMSO and canagliflozin treatments was not statistically significant. In contrast, phlorizin (3 mM) caused significant (P<0.05) inhibition of DNJ-induced currents in SGLT3-injected oocytes (73.5±4.2%; n = 14; Table 1).

Effect of Canagliflozin on the Relationship between BG and UGE

Two separate GGI studies were performed to characterize the relationship between BG and UGE in untreated and treated ZDF rats. In the first study, untreated ZDF rats given a GGI to raise BG from approximately 200 mg/dl to approximately 475 mg/dl did not experience appreciable UGE until BG levels were >400 mg/dl and RTG = 415±12 mg/dl. Canagliflozin treatment (1 mg/kg) notably lowered RTG in ZDF rats to 94±10 mg/dl (Figure 2). In the second study, an insulin infusion was given to lower BG to approximately 25 mg/dl, and then the GGI was given to slowly raise BG to approximately 300 mg/dl. In ZDF rats treated with canagliflozin (1 mg/kg), the relationship between BG and UGE remained well-described by a threshold relationship with negligible UGE occurring when BG<90 mg/dl and UGE increased in proportion to BG at higher BG levels, whereas virtually no UGE was observed in vehicle-treated animals in this study (Figure 2).

Figure 2. BG and UGE in untreated and CANA-treated ZDF rats during two GGI studies.

In the first study (GGI only), a GGI was given to untreated ZDF rats (n = 8) to raise BG from 212±24 mg/dl to ∼475 mg/dl over 90 minutes. In the second study (Insulin+GGI), ZDF rats (n = 6/group) were treated with either vehicle or canagliflozin (1 mg/kg), then given insulin to lower BG to 25±1 mg/dl, and finally given the GGI to slowly raise BG. BG and UGE were measured every 5 minutes. Results shown are mean ± S.E. GGI, graded glucose infusion; BG, blood glucose; UGE, urinary glucose excretion; ZDF, Zucker diabetic fatty rats; GG1, graded glucose infusion.

Effect of Canagliflozin on Glycemic Control in db/db Mice and ZDF Rats

In db/db mice, single doses of canagliflozin dose-dependently reduced non-fasting BG concentrations. The onset of the BG-lowering effect after a single dose was rapid, and BG levels in canagliflozin-treated mice (at 1 and 10 mg/kg doses) were significantly different from those of vehicle-treated mice at 1 hour after treatment (22% and 36% reduction of BG levels compared with that in vehicle-treated mice [P<0.5], respectively). This antihyperglycemic effect reached its peak at 6 hours (BG levels at 208±9.6 or 118±9.0 mg/dl in db/db mice treated with 1 or 10 mg/kg, respectively, compared with BG level of 479±3.9 mg/dl in vehicle-treated mice). To evaluate the chronic effect of canagliflozin on glycemic control, ZDF rats were treated with the compound at doses of 3, 10, or 30 mg/kg for 4 weeks. The non-fasting BG and HbA1c levels decreased in all canagliflozin-treated rats compared with the vehicle-treated group (Table 2). Canagliflozin treatment also reduced BG levels in ZDF rats following an OGTT (Table 2) after 4 weeks of treatment. Canagliflozin treatment improved beta-cell function as demonstrated by a 4-to-6-fold increase, relative to vehicle-treated animals, in the insulin/glucose ratio following an OGTT (Table 2).

Table 2. Effects of a 4-week treatment of canagliflozin on blood glucose and insulin levels in ZDF rats.

Effect of Canagliflozin on Body Weight Gain in DIO Mice and ZF Rats

In DIO mice, canagliflozin 30 mg/kg treatment for 4 weeks reduced BG levels, respiratory exchange ratio, and body weight gain (Table 3). In ZF rats treated with canagliflozin 3 mg/kg for 3 weeks, UGE was increased with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight. Relative to vehicle-treated ZF rats, canagliflozin-treated ZF rats had a reduction in respiratory exchange ratio. The weight of epididymal fat pads and liver tissues in compound-treated groups tended to be reduced. Feeding efficiency, defined as the body weight gain divided by the food intake, decreased in canagliflozin-treated ZF rats (Table 3).

Table 3. Effects of canagliflozin on body weight, glycemia, UGE, and respiratory exchange ratio in DIO mice and ZF rats.a.

Discussion

Based on in vitro assessments, canagliflozin is a potent and selective SGLT2 inhibitor. By inhibiting SGLT2, canagliflozin lowers the renal glucose resorptive capacity and increases UGE. The GGI studies performed demonstrate that the relationship between BG and UGE in canagliflozin-treated animals remains well described by a threshold relationship such that UGE in canagliflozin-treated animals remained near zero when BG levels were below RTG, and increased as BG increased when BG levels were above RTG. Canagliflozin treatment (1 mg/kg) lowered RTG in ZDF rats from 415±12 mg/dl to 94±10 mg/dl. RTG values in the untreated ZDF rats were considerably higher than values of 180–200 mg/dl commonly reported in humans [21], [22]. The higher RTG values observed in the ZDF rats compared with humans may be due in part to interspecies differences but may also be due to increased expression of renal glucose transporters that has been reported in diabetic rodents [23]–[25] and humans [26]. Consistent with the elevated renal glucose transporter expression, increased renal glucose re-absorptive capacity has been reported in humans with type 1 [27] and type 2 [28] diabetes.

In preclinical models of insulin resistance and diabetes, SGLT2 inhibitors improve beta-cell function and preserve islet morphology [29], [30]. As assessed using insulin/glucose ratio during the OGTT, canagliflozin improved beta-cell function in ZDF rats. SGLT2 inhibition may indirectly improve beta-cell function by reducing the toxic effects of hyperglycemia on the beta cell (i.e., reducing glucotoxicity) [31]. By reducing hyperglycemia via a non–insulin-dependent mechanism, SGLT2 inhibition decreases the demand on beta cells to secrete insulin. Increased insulin secretory demand results in endoplasmic reticulum stress, which in turn can lead to increases in beta-cell apoptosis [32]. A reduction in insulin secretory demand and, consequently, endoplasmic reticulum stress, could reduce beta-cell apoptosis, a condition increased in patients with T2DM [33]. Thus, by reducing demand on beta cells to secrete insulin as well as reducing glucotoxicity, SGLT2 inhibitors theoretically could reduce the rate of progression of T2DM [34]–[37].

In DIO mice and ZF insulin-resistant rats, caloric loss due to canagliflozin-induced increases in UGE was associated with reductions in body weight gain, epididymal fat mass, and hepatic weight. Additionally, a reduction in the respiratory exchange ratio, suggestive of increased fatty acid metabolism and/or reduced de novo lipogenesis, was observed in canagliflozin-treated animals. No compensatory increase in food consumption was detected in animals treated with canagliflozin. Although not directly assessed in this study, SGLT2 inhibitor-induced weight loss could indirectly improve insulin sensitivity. The reduction in liver weight and in respiratory quotient (RQ) observed in our studies are consistent with observations in gene-targeted mice lacking SGLT2 that indicate in mice lacking SGLT2 and fed with high-fat diet an increase in lipid oxidation, a reduction in hepatic glycogen content, and a decrease in RQ [38] relative to wild-type mice. In preclinical models of insulin resistance, improvements in insulin sensitivity, especially in hepatic insulin sensitivity, have been noted in animals treated with SGLT2 inhibitors [39].

A number of SGLT2 inhibitors, including canagliflozin, are in late-stage clinical development [12]–[14]. Many of the preclinical pharmacology findings with canagliflozin have been recapitulated in clinical trials with canagliflozin and other selective SGLT2 inhibitors. For instance, in patients with T2DM, treatment with SGLT2 inhibitors has led to improved glycemic control, reductions in body weight, and improvements in beta-cell function [40]–[43].

In summary, our current studies demonstrated that canagliflozin is a potent and selective SGLT2 inhibitor that lowers RTG, increases UGE, improves glycemic control, improves beta-cell function, reduces body weight, increases fatty acid oxidation, and reduces de novo lipogenesisin rodent models of insulin resistance and T2DM. These preclinical data suggest that canagliflozin may provide benefits beyond improving glycemic control in the treatment of T2DM and support the clinical development of canagliflozin to more fully characterize the benefit-risk profile of this agent in treating T2DM.

Acknowledgments

The authors greatly appreciate Hongchang Ma, who prepared the mRNA of SGLT3 for the oocyte experiment, and Stephanie DeCarlo, who provided technical assistance for the in vivo animal studies.

Footnotes

Competing Interests: The authors have read the journal's policy and have the following conflicts: Drs. Liang, Martin, Du, Conway, Polidori, and Demarest are employees of Johnson & Johnson Pharmaceutical Research & Development, LLC. Drs. Arakawa, Ueta, Matsushita, and Kuriyama are employees of Mitsubishi Tanabe Pharma Corporation, Japan. Canagliflozin (JNJ-28431754/TA-7284) is being developed by Johnson & Johnson Pharmaceutical Research & Development, LLC. in collaboration with Mitsubishi Tanabe Pharma Corporation. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Funding: Johnson & Johnson Pharmaceutical Research & Development, LLC. sponsored this study. Editorial assistance was provided by Phase Five Communications, Inc., and supported by Janssen Global Services, LLC. The authors are all employees of Johnson & Johnson Pharmaceutical Research & Development, LLC. or Mitsubishi Tanabe Pharma Corporation, and as such, designed the studies, participated in data collection and analysis, made the decision to publish, and prepared the manuscript.

References

• 1.Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047. [DOI] [PubMed] [Google Scholar]
• 2.Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81–86. doi: 10.2337/dc07-1572. [DOI] [PubMed] [Google Scholar]
• 3.Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32–43. doi: 10.1111/j.1365-2796.2006.01746.x. [DOI] [PubMed] [Google Scholar]
• 4.Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflügers Arch - Eur J Physiol. 2004;447:510–518. doi: 10.1007/s00424-003-1063-6. [DOI] [PubMed] [Google Scholar]
• 5.Kloeckener-Gruissem B, Vandekerckhove K, Nürnberg G, Neidhardt J, Zeitz C, et al. Mutation of solute carrier SLC16A12 associates with a syndrome combining juvenile cataract with microcornea and renal glucosuria. Am J Hum Genet. 2008;82:772–779. doi: 10.1016/j.ajhg.2007.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 6.Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133–141. doi: 10.2215/CJN.04010609. [DOI] [PubMed] [Google Scholar]
• 7.Wright EM. Genetic disorders of membrane transport: I. Glucose galactose malabsorption. Am J Physiol Gastrointest Liver Physiol. 1998;275:G879–G882. doi: 10.1152/ajpgi.1998.275.5.G879. [DOI] [PubMed] [Google Scholar]
• 8.Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2010;22:104–112. doi: 10.1681/ASN.2010030246. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 9.Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–38. doi: 10.1002/dmrr.532. [DOI] [PubMed] [Google Scholar]
• 10.Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037–1044. doi: 10.1172/JCI113157. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 11.Mather A, Pollock C. Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol. 2010;6:307–311. doi: 10.1038/nrneph.2010.38. [DOI] [PubMed] [Google Scholar]
• 12.Nair S, Wilding J. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34–42. doi: 10.1210/jc.2009-0473. [DOI] [PubMed] [Google Scholar]
• 13.Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–1277. doi: 10.1038/ki.2009.87. [DOI] [PubMed] [Google Scholar]
• 14.Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–559. doi: 10.1038/nrd3180. [DOI] [PubMed] [Google Scholar]
• 15.Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010;53:6355–6360. doi: 10.1021/jm100332n. [DOI] [PubMed] [Google Scholar]
• 16.Voss AA, Díez-Sampedro A, Hirayama BA, Loo DF, Wright EM. Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol. 2007;71:628–634. doi: 10.1124/mol.106.030288. [DOI] [PubMed] [Google Scholar]
• 17.Magni L, Raimondo DM, Bossi L, Man CD, De Nicolao G, et al. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol. 2007;6:804–12. doi: 10.1177/193229680700100603. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 18.Sha S, Devineni D, Ghosh A, Polidori D, Chien S, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669–672. doi: 10.1111/j.1463-1326.2011.01406.x. [DOI] [PubMed] [Google Scholar]
• 19.Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, et al. 2011. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors [published online ahead of print October 12, 2011] Diabetes Obes Metab doi: 10.1111/j.1463-1326.2011.01517.x. [DOI] [PubMed]
• 20.Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, et al. A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci USA. 2003;100:11753–11758. doi: 10.1073/pnas.1733027100. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 21.Nair S, Wilding J. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34–42. doi: 10.1210/jc.2009-0473. [DOI] [PubMed] [Google Scholar]
• 22.Rave K, Nosek L, Posner J, Heise T, Roggen K, et al. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes—results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant. 2006;21:2166–2171. doi: 10.1093/ndt/gfl175. [DOI] [PubMed] [Google Scholar]
• 23.Vestri S, Okamoto MM, Freitas HS, dos Santos RA, Nunes MT, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol. 2001;182:105–112. doi: 10.1007/s00232-001-0036-y. [DOI] [PubMed] [Google Scholar]
• 24.Freitas HS, Anhê GF, Melo KFS, Okamoto MM, Oliveira-SouzaM, et al. Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149:717–724. doi: 10.1210/en.2007-1088. [DOI] [PubMed] [Google Scholar]
• 25.Kamran M, Peterson R, Dominguez J. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943–948. doi: 10.1681/ASN.V86943. [DOI] [PubMed] [Google Scholar]
• 26.Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–3434. doi: 10.2337/diabetes.54.12.3427. [DOI] [PubMed] [Google Scholar]
• 27.Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971;28:101–109. doi: 10.3109/00365517109090668. [DOI] [PubMed] [Google Scholar]
• 28.Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30:125–129. doi: 10.1172/JCI102424. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 29.Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578–586. doi: 10.1038/sj.bjp.0703829. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 30.Nunoi K, Yasuda K, Adachi T, Okamoto Y, Shihara N, et al. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol. 2002;29:386–390. doi: 10.1046/j.1440-1681.2002.03671.x. [DOI] [PubMed] [Google Scholar]
• 31.Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabetic Med. 2009;26:1185–1192. doi: 10.1111/j.1464-5491.2009.02847.x. [DOI] [PubMed] [Google Scholar]
• 32.Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 2008;29:42–61. doi: 10.1210/er.2007-0015. [DOI] [PubMed] [Google Scholar]
• 33.Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. doi: 10.2337/diabetes.52.1.102. [DOI] [PubMed] [Google Scholar]
• 34.Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats. Life Sci. 2005;76:2655–2668. doi: 10.1016/j.lfs.2004.09.038. [DOI] [PubMed] [Google Scholar]
• 35.Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047–4058. doi: 10.1210/jcem.86.9.7713. [DOI] [PubMed] [Google Scholar]
• 36.Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009;609:148–154. doi: 10.1016/j.ejphar.2009.03.007. [DOI] [PubMed] [Google Scholar]
• 37.Oku A, Ueta K, Nawano M, Arakawa K, Kano-Ishihara T, et al. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol. 2000;391:183–192. doi: 10.1016/s0014-2999(00)00016-9. [DOI] [PubMed] [Google Scholar]
• 38.Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890–898. doi: 10.2337/db10-1328. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 39.Han S, Hagan DL, Taylor JR, Xin L, Meng W, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723–1729. doi: 10.2337/db07-1472. [DOI] [PubMed] [Google Scholar]
• 40.Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes on metformin. Diabetes. 2010;59:A78. [Google Scholar]
• 41.Wilding JP, Norwood P, T'joen C, Bastien A, List JF, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656–1662. doi: 10.2337/dc09-0517. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 42.List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657. doi: 10.2337/dc08-1863. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 43.Bailey CJ, Gross JL, Pieters A, Bastien A, List J. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233. doi: 10.1016/S0140-6736(10)60407-2. [DOI] [PubMed] [Google Scholar]